Related Experiment Video

Updated: Jul 6, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K

miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology

Joanna Kozłowska-Masłoń1,2, Kacper Guglas1,3, Tomasz Kolenda1,4

  • 1Laboratory of Cancer Genetics, Greater oland Cancer Centre, Poznan, Poland.

Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
|January 5, 2024
PubMed

Insights

Head and neck squamous cell carcinoma poses a global health challenge. MicroRNAs (miRNAs) show promise as biomarkers and therapeutic targets to improve diagnostics and treatment outcomes for these cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer-related deaths globally.
  • Late detection and tumor heterogeneity contribute to poor therapeutic outcomes in HNSCC.
  • Current diagnostic and therapeutic strategies for HNSCC require improvement.

Purpose of the Study:

  • To characterize microRNAs (miRNAs) as short non-coding RNAs (ncRNAs).
  • To review the current applications of miRNAs in HNSCC oncology.
  • To explore the potential of miRNAs as biomarkers and therapeutic targets for personalized medicine in HNSCC.

Main Methods:

  • Literature review of scientific reports on miRNAs in HNSCC.
  • Analysis of miRNA characteristics and their roles in cancer development.
  • Synthesis of current research on miRNA-based diagnostics and therapeutics.

Main Results:

  • MicroRNAs are key regulators of gene expression with significant roles in HNSCC.
  • miRNAs demonstrate potential as sensitive and specific biomarkers for early HNSCC detection.
  • miRNAs can be targeted for novel therapeutic interventions in HNSCC treatment.

Conclusions:

  • MicroRNAs offer a promising avenue for advancing HNSCC diagnostics and treatment.
  • Targeting miRNAs could lead to more personalized and effective cancer therapies.
  • Further research into miRNA mechanisms and clinical applications is warranted for HNSCC management.
Keywords:
HNSCCbiomarkershead and neck squamous cell carcinomamiRNAtherapeutic targets

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.6K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K